Lexeo Therapeutics (LXEO) Change in Account Payables (2022 - 2026)

Lexeo Therapeutics has disclosed Change in Account Payables across 5 years of filings, most recently posting -$1.6 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$1.6 million, down 131.03% year-over-year; the trailing twelve-month figure through Mar 2026 was -$8.3 million (down 220.6% YoY), and the FY2025 annual result was -$1.6 million, down 165.64% from the prior year.
• Change in Account Payables came in at -$1.6 million for Q1 2026 at Lexeo Therapeutics, down from $200000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $8.4 million in Q2 2025 to a low of -$15.3 million in Q3 2025.
• The 5-year median for Change in Account Payables is $342000.0 (2023), against an average of -$155714.3.
• Across the five-year window, Change in Account Payables soared 838.62% in 2024 and sank 660.91% in 2025, its largest moves.
• Lexeo Therapeutics' Change in Account Payables stood at -$1.2 million in 2022, then soared by 132.27% to $394000.0 in 2023, then slumped by 618.27% to -$2.0 million in 2024, then surged by 109.79% to $200000.0 in 2025, then sank by 898.0% to -$1.6 million in 2026.
• The last three Change in Account Payables figures came in at -$1.6 million (Q1 2026), $200000.0 (Q4 2025), and -$15.3 million (Q3 2025), per Business Quant data.